Valuation: BioGaia AB

Market Cap 11.71B 1.18B 1.04B 979M 892M 1.67B 113B 1.68B 4.54B 57.84B 4.43B 4.34B 186B P/E 2026 *
29.9x
P/E 2027 * 24x
Enterprise Value 11.04B 1.11B 977M 923M 841M 1.57B 107B 1.59B 4.28B 54.53B 4.18B 4.09B 175B EV / Sales 2026 *
6.6x
EV / Sales 2027 * 5.83x
Free-Float
80.82%
Yield 2026 *
3.54%
Yield 2027 * 3.78%
1 day-5.33%
3 months-5.33%
6 months-2.06%
Current year+5.48%
Current year 11.55
Extreme 11.55
12.2
1 year 10.24
Extreme 10.239
12.2
3 years 9
Extreme 9
12.7
5 years 8.42
Extreme 8.42
12.7
10 years 6.48
Extreme 6.48
13.56
Manager TitleAgeSince
Chief Executive Officer 60 2023-09-29
Director of Finance/CFO 59 2019-11-04
Chief Operating Officer 49 2020-12-31
Director TitleAgeSince
Chairman 77 2002-12-31
Chairman 76 2018-04-24
Director/Board Member 46 2014-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-5.33%-.--% - - 1.16B
-1.00%+0.41%+41.86%-5.58% 79.49B
+2.08%+29.11%+708.13%+102.59% 77.78B
-1.21%+0.77%-10.63%-30.06% 60.16B
-1.80%-2.29%-13.07%+28.02% 46.14B
+1.18%+3.03%+9.11%+169.01% 45.93B
+0.55%+5.61%+67.76%-10.75% 33.45B
-0.44%-1.13%+51.71%+110.88% 25.22B
-0.10%+3.21%+4.89%+155.64% 22.15B
+0.05%-2.42%+57.59%+97.38% 15.25B
Average -0.85%+4.15%+101.93%+68.57% 45.06B
Weighted average by Cap. -0.53%+6.41%+153.21%+54.62%

Financials

2026 *2027 *
Net sales 1.67B 169M 148M 140M 128M 239M 16.18B 240M 649M 8.27B 634M 620M 26.57B 1.9B 191M 168M 158M 144M 270M 18.33B 272M 735M 9.36B 718M 702M 30.09B
Net income 392M 39.53M 34.68M 32.76M 29.85M 55.88M 3.79B 56.28M 152M 1.94B 148M 145M 6.22B 486M 49.06M 43.05M 40.65M 37.05M 69.35M 4.7B 69.85M 188M 2.4B 184M 180M 7.72B
Net Debt -671M -67.66M -59.37M -56.07M -51.1M -95.66M -6.48B -96.34M -260M -3.31B -254M -249M -10.65B -660M -66.5M -58.35M -55.11M -50.22M -94.02M -6.37B -94.69M -255M -3.26B -250M -244M -10.46B
Logo BioGaia AB
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Employees
251
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
115.80SEK
Average target price
155.50SEK
Spread / Average Target
+34.28%

Quarterly revenue - Rate of surprise